Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Sultan Qaboos University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07342764CT.gov Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial | — | Not Yet Recruiting | — | — | — |
NCT07654179CT.gov Metformin as Adjunct Therapy in Depression-Obesity Comorbidity: Clinical and Genetic Evaluation | — | Active Not Recruiting | — | — | — |
NCT07485764CT.gov Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients | — | Not Yet Recruiting | — | — | — |
NCT07502001CT.gov Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin | — | Not Yet Recruiting | — | — | — |
NCT03686657CT.gov Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients | — | Not Yet Recruiting | — | — | — |
NCT07331389CT.gov A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin | — | Recruiting | — | — | — |
NCT07293325CT.gov Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity | — | Recruiting | — | — | — |
NCT06742710CT.gov Liraglutide Treatment in Obese Infertile PCOS Women | — | Recruiting | — | — | — |
NCT06775093CT.gov Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity | — | Not Yet Recruiting | — | — | — |
NCT05952882CT.gov Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility | — | Unknown | — | — | — |
Show 24 more trialsShow fewer
NCT06059287CT.gov The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics | — | Unknown | — | — | — |
NCT05815680CT.gov A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects | — | Completed | — | — | — |
NCT06390904CT.gov GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients | — | Active Not Recruiting | — | — | — |
NCT06379113CT.gov GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients | — | Recruiting | — | — | — |
NCT03593668CT.gov Effect and Safety of Benaglutide or Metformin in Patients With Simple Obesity Who Have Inadequate Weight Control | — | Unknown | — | — | — |
NCT03352869CT.gov Research of Exenatide for Overweight/Obese PCOS Patients With IGR | — | Completed | — | — | — |
NCT02796144CT.gov MEtformin and Lorcaserin for WeighT Loss in Schizophrenia | — | Terminated | — | — | — |
NCT02695810CT.gov The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes | — | Completed | — | — | — |
NCT03034941CT.gov Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients | — | Completed | — | — | — |
NCT02014740CT.gov Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes | — | Completed | — | — | — |
NCT02187250CT.gov PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome | — | Completed | — | — | — |
NCT02483299CT.gov Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome | — | Completed | — | — | — |
NCT02037672CT.gov PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome | — | Completed | — | — | — |
NCT02514629CT.gov Testosterone, Metformin, or Both, for Hypogonadism in Obese Males | — | Completed | — | — | — |
NCT01686828CT.gov T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin | — | Completed | — | — | — |
NCT01725126CT.gov To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes | — | Completed | — | — | — |
NCT01911468CT.gov Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin | — | Completed | — | — | — |
NCT01899430CT.gov Polycystic Ovary Syndrome and Liraglutide | — | Completed | — | — | — |
NCT01351753CT.gov Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity | — | Terminated | — | — | — |
NCT01457703CT.gov Reproductive Hormonal Alterations in Obesity | — | Completed | — | — | — |
NCT01896050CT.gov Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer | — | Completed | — | — | — |
NCT00775164CT.gov Pioglitazone Therapy in Obese Children With Insulin Resistance: A Randomized, Controlled Pilot Study | — | Withdrawn | — | — | — |
NCT00941382CT.gov Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients | — | Unknown | — | — | — |
NCT00099697CT.gov Biologic Effects of Dehydroepiandrosterone (DHEA) in Humans | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Letrozole (this asset) | Sultan Qaboos University | Approved | BB · 67 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Letrozole
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Infertility Disorder | — | P4 | BBB · 79 |
| Anovulation | — | P4 | BBB · 78 |
| Invasive Breast Carcinoma | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Letrozole in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/letrozole-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →